Sign in

You're signed outSign in or to get full access.

Alto Ingredients (ALTO)

--

Earnings summaries and quarterly performance for Alto Ingredients.

Recent press releases and 8-K filings for ALTO.

ALTO Ingredients Reports Q3 2025 Financial Results
ALTO
Earnings
Guidance Update
New Projects/Investments
  • ALTO Ingredients reported a significant improvement in its financial position for Q3 2025, with gross profit increasing by $18 million, net income by $17 million, and Adjusted EBITDA by $9 million compared to Q3 2024.
  • For Q3 2025, the company achieved net income of $14.2 million and Adjusted EBITDA of $21.4 million, resulting in basic and diluted net income per share of $0.19.
  • The company is applying for Section 45Z tax credits for its Alto Columbia and Alto Pekin Dry Mill facilities, estimated to total approximately $18 million in the next two years.
  • Positive regulatory trends, including the extension of the Section 45Z tax credit and momentum for national year-round E15 adoption, are expected to improve ALTO's earnings profile and increase its intrinsic valuation.
  • ALTO is focused on targeted projects to lower carbon intensity, increase CO2 utilization, and continue cost reduction, while also leveraging various certifications to differentiate its products and deepen customer relationships.
Nov 5, 2025, 10:00 PM
Alto Ingredients Reports Strong Q3 2025 Financial Results and Strategic Progress
ALTO
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
  • Alto Ingredients reported significant financial improvements in Q3 2025 compared to Q3 2024, with net income improving $17 million to $13.9 million or $0.19 per share, and Adjusted EBITDA growing $9.2 million to $21.4 million.
  • The company anticipates earning $0.10 per gallon in Section 45Z tax credits at its Columbia plant for 2025, potentially increasing to $0.20 per gallon at Columbia and $0.10 per gallon at Pekin dry mill in 2026, which could total $18 million in aggregate gross credits over two years. Overall CO2 utilization has improved following the Alto Carbonic acquisition in early 2025.
  • Increased renewable fuel export sales contributed $5.6 million more to gross profit in Q3 2025, and the newly signed California Assembly Bill 30 is expected to unlock significant demand for domestically produced ethanol. SG&A expenses improved $1 million to $6.5 million due to cost reduction initiatives.
  • Alto Ingredients is evaluating options for its Magic Valley facility, including sale, CO2 utilization, and 45Z tax credits, and is planning to build a second alcohol loadout dock at Pekin to improve capacity.
Nov 5, 2025, 10:00 PM
Alto Ingredients, Inc. Reports Strong Third Quarter 2025 Financial Results
ALTO
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
  • Alto Ingredients, Inc. reported net income attributable to common stockholders of $13.9 million, or $0.19 per share, for the third quarter of 2025, a significant improvement from a net loss of $2.8 million, or $0.04 per share, in the third quarter of 2024.
  • Gross profit for Q3 2025 increased to $23.5 million, up $17.5 million from $6.0 million in Q3 2024.
  • Adjusted EBITDA for Q3 2025 grew to $21.4 million, an increase of $9.2 million compared to $12.2 million in Q3 2024.
  • These financial improvements were driven by increased renewable fuel export sales, greater demand for liquid CO2, and successful cost reduction efforts.
Nov 5, 2025, 9:15 PM
Alto Ingredients, Inc. Reports Strong Q3 2025 Results with Return to Profitability
ALTO
Earnings
New Projects/Investments
  • Alto Ingredients, Inc. reported a net income of $13.9 million, or $0.19 per share, for the third quarter ended September 30, 2025, a significant improvement from a net loss of $2.8 million, or $0.04 per share, in the same period of 2024.
  • The company's gross profit increased to $23.5 million in Q3 2025, up from $6.0 million in the prior year quarter, and Adjusted EBITDA grew to $21.4 million from $12.2 million, despite a decrease in net sales to $241.0 million.
  • For the nine months ended September 30, 2025, the net loss attributable to common stockholders was reduced to $9.4 million, or $0.13 per share, compared to a $18.2 million loss, or $0.25 per share, in the same period of 2024, with Adjusted EBITDA turning positive at $16.7 million from negative $0.8 million.
  • Management attributed the improved performance to increased renewable fuel export sales, greater demand for liquid CO2, and cost reduction efforts, including benefits from the 2025 Carbonic acquisition.
Nov 5, 2025, 9:05 PM
Alto Ingredients Discusses Strategic Diversification and Growth Opportunities
ALTO
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
  • Alto Ingredients has strategically diversified its operations by selling West Coast facilities and acquiring Midwest plants, expanding its product portfolio beyond renewable fuels to serve industrial, pharmaceutical, beverage, and agricultural markets.
  • The company implemented cost reduction measures, including $8 million in annual staffing expense reductions recognized in Q2, and is focusing on projects with shorter paybacks and higher ROI.
  • Significant growth opportunities are anticipated from CO2 utilization, with the Pekin campus capable of producing 600,000 metric tons of CO2 annually, and from regulatory tailwinds such as 45Z transferable tax credits. The Columbia facility is projected to qualify for $4 million in gross 45Z value in 2025, potentially doubling to $8 million in 2026, and the Pekin dry mill could add $6 million starting 2026.
  • California's approval of year-round E15 blends presents a potential demand increase of over 600 million gallons/year, further benefiting Alto Ingredients' West Coast presence.
Oct 21, 2025, 8:00 PM
Alto Ingredients Discusses Strategic Diversification and Growth Opportunities
ALTO
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
  • Alto Ingredients has strategically diversified its operations, moving from a West Coast ethanol focus to acquiring Midwest assets and rebranding in 2021. The company now produces a broader portfolio of products for industrial, pharmaceutical, beverage, agricultural, and renewable fuel markets.
  • The company is implementing cost reduction measures, including an $8 million annual expense reduction from staffing adjustments in Q1 2025.
  • Significant growth opportunities are identified in CO2 utilization, with the PEAKIN campus capable of producing 600,000 metric tons of CO2 per year. The Columbia, Oregon facility's acquisition of a CO2 processing plant on January 1, 2025, has already stabilized earnings.
  • Regulatory tailwinds from 45Z transferable tax credits (2025-2029) are expected to generate substantial value, with the Columbia, Oregon facility projected to yield $4 million in gross 45Z value in 2025, potentially doubling to $8 million in 2026. The PEAKIN campus dry mill could add another $6 million starting in 2026.
  • Increased support for E15 blends, including California's recent approval for year-round use, is anticipated to boost demand by 5 to 7 billion gallons nationally and over 600 million gallons annually in California, positioning Alto Ingredients to capitalize on increased renewable fuel sales.
Oct 21, 2025, 8:00 PM
Alto Ingredients Applauds California's Approval of E15 Fuel Sales
ALTO
New Projects/Investments
Revenue Acceleration/Inflection
  • Alto Ingredients, Inc. (ALTO) welcomes the signing of Assembly Bill 30 by Governor Gavin Newsom, which authorizes the sale of E15 fuel (a gasoline blend containing 15% ethanol) throughout California.
  • This legislation is anticipated to increase ethanol consumption by more than 600 million gallons per year.
  • Alto Ingredients is positioned to leverage its annual ethanol production capacity of up to 350 million gallons to supply California's low carbon transportation fuels market.
Oct 6, 2025, 12:30 PM
Alto Neuroscience Faces Federal Securities Class Action Lawsuit
ALTO
Legal Proceedings
Demand Weakening
Profit Warning
  • Faruqi & Faruqi, LLP is investigating and a federal securities class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO), alleging the company made false and misleading statements regarding the effectiveness and prospects of ALTO-100 for treating Major Depressive Disorder (MDD).
  • The lawsuit stems from Alto's October 22, 2024, announcement that ALTO-100 failed to meet its primary endpoint in a Phase 2b trial, which resulted in Alto's stock price falling $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • Investors who purchased Alto common stock during the Class Period between February 2, 2024, and October 22, 2024, are encouraged to contact the firm, with a lead plaintiff deadline of September 19, 2025.
Sep 11, 2025, 11:20 PM